Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.82%
0%
3.82%
6 Months
24.07%
0%
24.07%
1 Year
42.38%
0%
42.38%
2 Years
42.38%
0%
42.38%
3 Years
-4.17%
0%
-4.17%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Laboratorio Farmaceutico Erfo SpA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.24%
EBIT Growth (5y)
-0.50%
EBIT to Interest (avg)
0.30
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.62
Tax Ratio
17.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.23%
ROE (avg)
7.11%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.95
EV to EBIT
16.18
EV to EBITDA
15.06
EV to Capital Employed
1.88
EV to Sales
2.11
PEG Ratio
0.49
Dividend Yield
NA
ROCE (Latest)
3.10%
ROE (Latest)
6.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
5.70
4.60
23.91%
Operating Profit (PBDIT) excl Other Income
1.00
1.20
-16.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.60
0.70
-14.29%
Operating Profit Margin (Excl OI)
54.00%
126.00%
-7.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 23.91% vs -4.17% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -14.29% vs -41.67% in Dec 2022
About Laboratorio Farmaceutico Erfo SpA 
Laboratorio Farmaceutico Erfo SpA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






